A number of research firms have changed their ratings and price targets for Dyne Therapeutics (NASDAQ: DYN):
- 9/4/2024 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
- 9/3/2024 – Dyne Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $55.00 price target on the stock.
- 8/30/2024 – Dyne Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
- 8/24/2024 – Dyne Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
- 8/17/2024 – Dyne Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
- 8/16/2024 – Dyne Therapeutics had its price target raised by analysts at Stifel Nicolaus from $41.00 to $66.00. They now have a “buy” rating on the stock.
- 8/15/2024 – Dyne Therapeutics had its price target raised by analysts at Guggenheim from $45.00 to $50.00. They now have a “buy” rating on the stock.
- 8/14/2024 – Dyne Therapeutics had its price target raised by analysts at Morgan Stanley from $48.00 to $52.00. They now have an “overweight” rating on the stock.
- 8/13/2024 – Dyne Therapeutics had its price target raised by analysts at Piper Sandler from $43.00 to $53.00. They now have an “overweight” rating on the stock.
- 8/13/2024 – Dyne Therapeutics had its price target raised by analysts at HC Wainwright from $48.00 to $55.00. They now have a “buy” rating on the stock.
Dyne Therapeutics Stock Down 1.7 %
NASDAQ DYN opened at $32.47 on Tuesday. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45. The firm has a 50-day moving average price of $41.52 and a 200 day moving average price of $33.12. The stock has a market capitalization of $3.26 billion, a P/E ratio of -8.18 and a beta of 1.07.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.
Insider Transactions at Dyne Therapeutics
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its stake in Dyne Therapeutics by 4.3% during the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after purchasing an additional 352 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Amalgamated Bank boosted its holdings in Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the last quarter. Principal Financial Group Inc. grew its position in Dyne Therapeutics by 5.9% during the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares during the period. Finally, Wetzel Investment Advisors Inc. acquired a new stake in Dyne Therapeutics during the first quarter worth about $28,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Options Trading – Understanding Strike Price
- Why Block’s Key Components Make It a Solid Investment Choice
- 3 Tickers Leading a Meme Stock Revival
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- How to Plot Fibonacci Price Inflection Levels
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Dyne Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.